Literature DB >> 11372590

High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.

E García-Martín1, C Martínez, J M Ladero, F J Gamito, J A Agúndez.   

Abstract

OBJECTIVE: To search for ethnic variability in the impact of cytochrome P450 2C9 (CYP2C9) polymorphism.
METHODS: CYP2C9 allelic variants related to impaired CYP2C9 metabolism were analysed in genomic DNA from 157 Spanish healthy subjects using amplification-restriction and sequencing procedures.
RESULTS: The frequency for CYP2C9 mutated alleles is higher among the Spanish subjects analysed than that reported for other Caucasian individuals: CYP2C9*2, 0.143 and CYP2C9*3, 0.162 (P = 0.0001). Nearly 10% of the individuals studied are expected to metabolise deficiently CYP2C9 substrates.
CONCLUSION: In some Caucasian populations the impact of the CYP2C9 polymorphism may be much higher than that estimated from genotyping studies published to date.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372590     DOI: 10.1007/s002280100264

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.

Authors:  Maria Burian; Sabine Grösch; Irmgard Tegeder; Gerd Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.

Authors:  Faiza Yasmeen; Muhammad Bilal Ghafoor; Abdul Wadood Khalid; Waqas Latif; Shahida Mohsin; Shagufta Khaliq
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

5.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors:  K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

6.  Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis.

Authors:  Sergi Mas; Anna Crescenti; Jose M Vidal-Taboada; Salvador Bergoñon; Fernando Cuevillas; Nuria Laso; Rafael Molina; Antonio Ballesta; Amalia Lafuente
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 7.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.

Authors:  Heydy V Bravo-Villalta; Koujirou Yamamoto; Katsunori Nakamura; Ana Bayá; Yuko Okada; Ryuya Horiuchi
Journal:  Eur J Clin Pharmacol       Date:  2005-03-18       Impact factor: 2.953

9.  The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Authors:  Carmen Martínez; Elena García-Martín; Gerardo Blanco; Francisco J G Gamito; José M Ladero; José A G Agúndez
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

10.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.